NCT03559387 is a Phase 2 clinical trial of ANF-RHO™ in Chemotherapy-induced Neutropenia, sponsored by Prolong Pharmaceuticals.

Who is sponsoring NCT03559387?

NCT03559387 is sponsored by Prolong Pharmaceuticals.

What drugs are being tested in NCT03559387?

Interventions in NCT03559387: ANF-RHO™, Neulasta®.

What condition does NCT03559387 study?

NCT03559387 studies Chemotherapy-induced Neutropenia.

Is NCT03559387 still recruiting?

NCT03559387 is currently terminated. Last updated 12 February 2019.

Last reviewed 2019-02-12 · How we verify

NCT03559387

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Randomized Phase 2, Dose-finding Efficacy, Safety Study of ANF-RHO™ Versus Neulasta® in Chemotherapy-Induced Neutropenia

Terminated Phase 2 Last updated 12 February 2019

What this trial tests

Phase 2 trial testing ANF-RHO™ in Chemotherapy-induced Neutropenia in 9 participants. Terminated before completion.

Timeline

3 August 2017

Primary endpoint
18 April 2018

22 May 2018

Quick facts

Lead sponsor	Prolong Pharmaceuticals
Phase	Phase 2
Status	Terminated
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	9
Start date	3 August 2017
Primary completion	18 April 2018
Estimated completion	22 May 2018
Sites	8 locations across France, Netherlands

Drugs / interventions tested

ANF-RHO™
Neulasta®

Conditions studied

Chemotherapy-induced Neutropenia — all drugs for Chemotherapy-induced Neutropenia →

Sponsor

Prolong Pharmaceuticals — full company profile →

Who can join

18 and older, female only, with Chemotherapy-induced Neutropenia. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Randomized, Open-Label study to determine the dose, efficacy, safety and pharmacokinetic profile of ANF-RHO™ with once-per-cycle injection in comparison with Neulasta in Breast Cancer patients at high risk of developing Chemotherapy-Induced Neutropenia

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Chemotherapy-induced Neutropenia

Currently open trials in the same condition.

NCT06809101 — Home Monitoring of Complete Blood Count Performed by Patients - a Pilot Study on the Implementation Process in South Bal · recruiting
NCT06537726 — Breath Analysis for the Detection of Invasive Fungal Infections · recruiting
NCT07096479 — Telpegfilgrastim Injection to Reduce the Risk of Neutropenia in Patients With Solid Tumor · recruiting
NCT05245487 — Danish Elder Lymphoma Patient Hematopoietic Investigation · recruiting

Other Prolong Pharmaceuticals trials

Trials by the same sponsor.

NCT04677777 — Safety Study of PP-007 in Subjects With Acute Ischemic Stroke · Phase 1 · completed
NCT02950857 — A Study of EPEG in Beta Thalassemia Patients · Phase 1 · completed
NCT02437422 — Study to Assess the Safety and Impact on Humoral Sensitization of SANGUINATE in Patients With End Stage Renal Disease · Phase 1 · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03559387 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Prolong Pharmaceuticals
Last refreshed: 12 February 2019

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03559387.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing